LONDON, Feb. 4, 2014 /PRNewswire/ -- Edison's first report on Cytori Therapeutics, Cardiac Celution, discusses the use of concentrated adipose (fat) derived regenerative cells (ADRC) from the patient, which, when injected into damaged tissues, appear to trigger their healing. Cytori sells Celution, point-of-care disposables and a bedside device to prepare ADRC in 90 minutes or less. The procedure is flexible to use, with a potentially broad range of indications and an affordable price point.
We value Cytori at $230m or $3.10/share using a pre-tax 2025 multiple of 15x, which suggests the company offers a strong investment case in cell therapy.
For the full report see: www.edisoninvestmentresearch.com/research/company/cytori-therapeutics
All reports published by Edison are available to download free of charge from its website www.edisongroup.com.
Key links/tags: Healthcare, equipment, services, cell therapy, regenerative, cardiology, heart, ADRC
Overview of company: Cytori Therapeutics produces concentrated regenerative cells from adipose tissue using a bedside device and disposables. The unit is sold in Japan and the EU. The cells are administered to damaged heart muscle to improve heart function. There is also a US government (BARDA) contract to develop regenerative cells for burns therapy and a hamstring repair indication. Lorem Vascular will sell in China and South-East Asia.
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at www.edisongroup.com and connect with Edison on:
SOURCE Edison Investment Research